Table 1.
Characteristics of the included studies in this meta-analysis.
| References | Analysis of survival data | Neoadjuvant or adjuvant | Number of patients | Chemotherapy regimen | Region | Test tissue | Ki-67 cut off value (%) | ER/PR cut off value (%) |
|---|---|---|---|---|---|---|---|---|
| Toyama et al. (17) | UVA | Adjuvant | 71 | 5-FU | Asian | Operative specimen | 10 | 10 |
| Trere et al. (18) | Survival Curve | Adjuvant | 24 | CMF | European | Operative specimen | 20 | 10 |
| Lee et al. (19) | MVA | Adjuvant | 1550 | NR | Asian | Operative specimen | 20 | 10 |
| Nishimura et al. (20) | MVA | Adjuvant | 356 | CMF, CE(F), Taxane | Asian | Operative specimen | 20 | 10 |
| Wang et al. (21) | UVA | Adjuvant | 42 | Paclitaxel-based | Asian | Operative specimen | 30 | 10 |
| Keam et al. (23) | MVA | Neoadjuvant | 105 | Taxel/anthracyclin-based | Asian | Pre-NAC | 10 | 10 |
| Li et al. (24) | UVA | Adjuvant | 125 | NR | Asian | Operative specimen | NR | 10 |
| Masuda et al. (25) | MVA | Neoadjuvant | 33 | Taxel/anthracyclin-based | Asian | Pre-NAC | 50 | 10 |
| Miyashita et al. (26) | MVA | Adjuvant | 102 | NR | Asian | Operative specimen | 40 | 1 |
| Kashiwagi et al. (22) | Survival Curve | Adjuvant | 190 | 5-FU/anthracyclin-based | Asian | Operative specimen | 30 | 1 |
| Munzone et al. (27) | Survival Curve | Adjuvant | 496 | Anthracyclin-based, CMF | European | Operative specimen | 35 | 1 |
| Ryu et al. (28) | UVA | Adjuvant | 94 | Anthracyclin-based | Asian | Operative specimen | 10 | 10 |
| Xue et al. (29) | MVA | Adjuvant | 913 | Taxel/anthracyclin-based, CMF | Asian | Operative specimen | 14 | 5 |
| Huang et al. (30) | MVA | Adjuvant | 185 | Taxel/anthracyclin-based, CMF | Asian | Operative specimen | 20 | 1 |
| Milde-Langosch et al. (31) | MVA | Adjuvant | 95 | CMF/EC | European | Operative specimen | NR | NR |
| Xu et al. (32) | MVA | Adjuvant | 122 | CMF | Asian | Operative specimen | 10 | 10 |
| Yamashita et al. (33) | MVA | Adjuvant | 82 | NR | Asian | Operative specimen | 30 | 1 |
| Zhang et al. (34) | MVA | Adjuvant | 428 | Taxel/anthracyclin-based | Asian | Operative specimen | 14 | 10 |
| Zhou et al. (35) | UVA | Adjuvant | 31 | Taxel/anthracyclin-based, CMF | Asian | Operative specimen | 10 | 10 |
| Schmidt et al. (38) | Survival Curve | Adjuvant/neoadjuvant | 103 | Taxel-based | European | NR | 14 | 1 |
| Park et al. (36) | UVA | Adjuvant | 1551 | NR | Asian | Operative specimen | 50 | 1 |
| Pistelli et al. (37) | UVA | Adjuvant | 81 | Anthracyclin-based, CMF | European | Operative specimen | 30 | 10 |
| Hao et al. (40) | MVA | Adjuvant | 571 | NR | Asian | Operative specimen | 35 | 1 |
| Khalifa et al. (41) | UVA | Adjuvant/neoadjuvant | 106 | Taxel/anthracyclin-based | European | Pre-NAC | 20 | 10 |
| Liu et al. (42) | UVA | Adjuvant | 154 | NR | Asian | Operative specimen | 30 | 1 |
| Asano et al. (39) | UVA | Neoadjuvant | 61 | Taxel/anthracyclin-based | Asian | Pre-NAC | 14 | 1 |
| Wang et al. (43) | MVA | Adjuvant | 363 | Taxel/anthracyclin-based | Asian | Operative specimen | 40 | 1 |
| Yang and Han (50) | UVA | Adjuvant | 199 | NR | Asian | Operative specimen | 14 | NR |
| Yue et al. (44) | MVA | Adjuvant | 192 | NR | Others | Operative specimen | 50 | 1 |
| Zakaria et al. (45) | MVA | Adjuvant | 77 | Taxel/anthracyclin-based | Others | Operative specimen | 10 | 10 |
| Zhong et al. (46) | UVA | Adjuvant | 90 | NR | Asian | Operative specimen | 14 | 1 |
| Ieni et al. (47) | MVA | Adjuvant | 65 | NR | European | Operative specimen | 20 | 1 |
| Kwon et al. (48) | UVA | Adjuvant/neoadjuvant | 230 | Taxel/anthracyclin-based | Asian | Pre-NAC | 20 | 1 |
| Najafi et al. (49) | Survival Curve | Adjuvant | 119 | NR | Asian | Operative specimen | 20 | 10 |
| Wang and Liu (51) | MVA | Adjuvant | 110 | NR | Asian | Operative specimen | 20 | NR |
UVA, unitivariate analysis; MVA, multivariate analysis; NR, not reported; NAC, neoadjuvant chemotherapy; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; CEF, cyclophosphamide, epirubicin, and 5-FU; EC, epirubicin/cyclophosphamide.